VKH
ALDX icon

Virtu KCG Holdings’s Aldeyra Therapeutics ALDX Stock Holding History

Virtu KCG Holdings’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$104K Buy
+22,431
New +$103K ﹤0.01% 2404

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Virtu KCG Holdings's ALDX Position: Q2 2017 in Review

Virtu KCG Holdings opened a new position in Aldeyra Therapeutics (ALDX) in Q2 2017: 22,431 shares worth $104K. The stake represents ﹤0.01% of the portfolio and ranks #2404 among its holdings.

26 funds tracked by Wall St. Rank hold ALDX as of Q2 2017.

  • Virtu KCG Holdings held 22,431 shares of Aldeyra Therapeutics worth $104K as of Q2 2017.
  • Aldeyra Therapeutics was a new Virtu KCG Holdings position in Q2 2017.
  • Aldeyra Therapeutics made up ﹤0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #2404 holding.
  • 26 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.